IMV Announces Board Retirement
February 14 2020 - 6:05AM
Business Wire
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage
biopharmaceutical company pioneering a novel class of
immunotherapies, today announced that Albert Scardino will retire
from the IMV Board of Directors effective February 28th, 2020.
Mr. Scardino, 71, joined the board in 2011 and served as
Chairman from 2011 to 2016. After a career in journalism in the US
and the UK, he became an independent investor and company director.
With his wife, Marjorie Scardino, he has owned a significant
shareholding in IMV since 2004.
“It has been a source of humility to work with so many talented
scientists and committed shareholders for so many years,” Mr.
Scardino said. “The discoveries in immunology made by the science
faculty at Dalhousie University in Halifax more than 25 years ago
may improve the prevention and treatment of many human diseases.
I’m grateful for having had the chance to support this work.”
IMV’s Board and Management thank him for his dedication and
support of the Company and wish Albert well in all his future
endeavors.
About IMV
IMV Inc. is a clinical stage biopharmaceutical company dedicated
to making immunotherapy more effective, more broadly applicable,
and more widely available to people facing cancer and other serious
diseases. IMV is pioneering a new class of immunotherapies based on
the Company’s proprietary drug delivery platform. This patented
technology leverages a novel mechanism of action that enables the
programming of immune cells in vivo, which are aimed at generating
powerful new synthetic therapeutic capabilities. IMV’s lead
candidate, DPX-Survivac, is a T cell-activating immunotherapy that
combines the utility of the platform with a target: survivin. IMV
is currently assessing DPX-Survivac in advanced ovarian cancer, as
well as a combination therapy in multiple clinical studies with
Merck’s Keytruda®. Connect at www.imv-inc.com.
IMV Forward-Looking Statements
This press release contains forward-looking information under
applicable securities law. All information that addresses
activities or developments that we expect to occur in the future is
forward-looking information. Forward-looking statements are based
on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual
results may differ materially from those set forth in this press
release due to risks affecting the Corporation, including access to
capital, the successful completion of clinical trials and receipt
of all regulatory approvals. IMV Inc. assumes no responsibility to
update forward-looking statements in this press release except as
required by law. These forward-looking statements involve known and
unknown risks and uncertainties and those risks and uncertainties
include, but are not limited to, our ability to access capital, the
successful and timely completion of clinical trials, the receipt of
all regulatory approvals and other risks detailed from time to time
in our ongoing quarterly filings and annual information form.
Investors are cautioned not to rely on these forward-looking
statements and are encouraged to read IMV’s continuous disclosure
documents, including its current annual information form, as well
as its audited annual consolidated financial statements which are
available on SEDAR at www.sedar.com and on EDGAR at
www.sec.gov/edgar.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200214005026/en/
Investor Relations Marc Jasmin, Senior Director,
Investor Relations, IMV O: (902) 492-1819 ext. 1042 M: (514)
617-9481 E:mjasmin@imv-inc.com
Josh Rappaport, Director, Stern IR O: (212) 362-1200 E:
josh.rappaport@sternir.com
Media Delphine Davan, Director, Communications,
IMV M: (514) 968-1046 E:ddavan@imv-inc.com
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024